Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

QR Code

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

Bibliographic Details
Main Authors:	Miles, D., de haas, S., Dirix, L., Romieu, G., Chan, Arlene, Pivot, X., Tomczak, P., Provencher, L., Cortes, J., Delmar, P., Scherer, S.
Format:	Journal Article
Published:	Nature Publishing Group 2013
Online Access:	http://hdl.handle.net/20.500.11937/27277

Similar Items

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2010)

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2010)

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
by: Gianni, L., et al.
Published: (2013)

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
by: De Boer, R., et al.
Published: (2012)

HER2 positive metastatic breast cancer: What happens after first line failure?
by: Chan, Arlene
Published: (2016)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan, Arlene, et al.
Published: (2012)

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2014)

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
by: Cameron, David, et al.
Published: (2013)

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study
by: Bergh, J., et al.
Published: (2012)

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2013)

Capecitabine and vinorelbine in metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2009)

TILs in metastatic breast cancer—no surprises, but more questions
by: Chan, Arlene
Published: (2017)

Randomized Phase 111 Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endrocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
by: Wolff, A., et al.
Published: (2013)

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
by: Wolff, A., et al.
Published: (2013)

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
by: Baselga, J., et al.
Published: (2017)

Prevalence of Excessive Tearing in Women With Early Breast Cancer Receiving Adjuvant Docetaxel-Based Chemotherapy
by: Chan, Arlene, et al.
Published: (2013)

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
by: Middleton, Gary, et al.
Published: (2017)

Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
by: Chan, Arlene
Published: (2016)

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer
by: Cinieri, S., et al.
Published: (2017)

Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study
by: Au, H., et al.
Published: (2013)

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial
by: Eiermann, W., et al.
Published: (2011)

Vomiting in docetaxel chemotherapy: which to blame, dose or gene?
by: Jabir, Rafid, et al.
Published: (2014)

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
by: Mackey, J., et al.
Published: (2016)

Frenceay finds her strength
by: Y.P. , Sivam
Published: (2012)

BCL-2, HER1, HER2, HER3 and HER4 expression in primary colorectal adenocarcinoma
by: Ahmad Zubir, Nurul Mahirah
Published: (2017)

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
by: Chan, Arlene, et al.
Published: (2016)

HerMES: Far infrared properties of known AGN in the HerMES fields
by: Hatziminaoglou, E., et al.
Published: (2010)

Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma
by: Grill, Jacques, et al.
Published: (2018)

Her beauty & her terror : portrait of an archetypal land
by: Frantom, Michelle
Published: (2014)

An investigation of metastatic colorectal cancer
by: Asiri, Abutaleb
Published: (2018)

Biocompatible hyperbranched polyglycerol modified ß-cyclodextrin derivatives for docetaxel delivery
by: Xu, Z., et al.
Published: (2017)

Development and characterization of docetaxel and curcumin-loaded aerosolized nanoemulsion for pulmonary cancer
by: Asmawi, Azren Aida
Published: (2020)

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab
by: Chan, Arlene, et al.
Published: (2012)

It's her platform
by: Lim, Teik Huat
Published: (2018)

Expression of HER4 isoforms and HER4 localisation in HER2 negative breast cancer cell lines
by: Ali, Nursyazana Aqilah
Published: (2021)

Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability
by: Badran, Mohamed M., et al.
Published: (2018)

Development and validation of HPLC method for quantification of docetaxel in palm-based nanoemulsion aerosols
by: Asmawi, Azren Aida, et al.
Published: (2020)

HerMES: The SPIRE confusion limit
by: Nguyen, H., et al.
Published: (2010)

Her ideal platform
by: Lim, Teik Huat
Published: (2018)

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase 11 study
by: Hyams, D., et al.
Published: (2013)

Cannot write session to /tmp/vufind_sessions/sess_16cggan4mh7220hu9mugtot2uk